Kimura I, Wakasono S, Kimura M
Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Japan.
Jpn J Pharmacol. 1995 May;68(1):129-32. doi: 10.1254/jjp.68.129.
We examined the effect of peripheral administration of cholecystokinin (CCK)-8S on spontaneous acetylcholine (ACh) release from the frontal cortex and its prevention by loxiglumide, L-364,718 and L-365,260 in freely moving rats using intracerebral microdialysis. Subcutaneously (s.c.) administered CCK-8S at 10 and 30 micrograms/kg significantly decreased the release of ACh. The inhibitory effect of 10 micrograms/kg (s.c.) CCK-8S was prevented by loxiglumide, a mixed type of CCK-A and -B-receptor antagonist, at 1 mg/kg (intraperitoneal) and 40 micrograms/rat (intracerebroventricular, i.c.v.); L-364,718, a CCK-A-receptor antagonist, at 125 and 250 ng/rat (i.c.v.); and L-365,260, a CCK-B-receptor antagonist at 250 ng/rat (i.c.v.). These results demonstrate that peripherally administered CCK-8S inhibits spontaneous ACh release from the frontal cortex through both central CCK-A (mainly) and -B receptors.
我们使用脑内微透析技术，研究了外周给予胆囊收缩素（CCK）-8S对自由活动大鼠额叶皮质乙酰胆碱（ACh）自发释放的影响，以及洛西格列胺、L-364,718和L-365,260对其的预防作用。皮下注射10微克/千克和30微克/千克的CCK-8S可显著降低ACh的释放。1毫克/千克（腹腔注射）和40微克/只（脑室内注射，i.c.v.）的CCK-A和-B受体混合型拮抗剂洛西格列胺可预防10微克/千克（皮下注射）CCK-8S的抑制作用；CCK-A受体拮抗剂L-364,718，剂量为125纳克/只和250纳克/只（脑室内注射）；CCK-B受体拮抗剂L-365,260，剂量为250纳克/只（脑室内注射）。这些结果表明，外周给予的CCK-8S通过中枢CCK-A（主要）和-B受体抑制额叶皮质ACh的自发释放。
